India  

AstraZeneca shares down after report it approached Gilead

Video Credit: Reuters Studio - Duration: 01:09s - Published
AstraZeneca shares down after report it approached Gilead

AstraZeneca shares down after report it approached Gilead

Shares in Britain's AstraZeneca opened lower on Monday after a report it had approached U.S. rival Gilead Sciences about a possible merger.

Ciara Lee reports

0
shares
ShareTweetSavePostSend
 

Shares in Britain's AstraZeneca fell over 2% in early trades on Monday (June 8).

After a report from

Class="kln">Bloomberg suggested it had approached U.S. rival Gilead Sciences about a possible merger.

A union would create one of the world's largest drug companies.

And together, the two companies would have a market capitalisation of around $232 billion.

It would also unite two drugmakers at the forefront of efforts to fight the new coronavirus.

But that could be politically complicated as governments seek control over potential treatments.

And there were some raised eyebrows over the report on Monday.

One analyst questioned why the British group would seek to tie up with a company that is growing at a slower pace.

The report by Bloomberg said AstraZeneca contacted Gilead last month, but that its U.S. rival was not interested in combining with another big pharmaceuticals company.

Early research has shown that one of Astra's cancer drugs may help hospitalised patients get through the worst of Covid-19.

And Gilead Science's antiviral drug remdesivir has proven to provide a modest benefit to some patients with moderate symptoms of the illness.




πŸ’‘ newsR Knowledge: Other News Mentions

AstraZeneca British-Swedish pharmaceutical company

Europe Inc. plunges into the red [Video]

Europe Inc. plunges into the red

A huge day for earnings Thursday saw bleak numbers for European corporate titans including Renault, Volkswagen and Airbus. But drugmaker AstraZeneca sounded a more positive note. Julian Satterthwaite reports.

Credit: Reuters Studio    Duration: 01:37Published
Sanofi eyes vaccine approval by early 2021 [Video]

Sanofi eyes vaccine approval by early 2021

French drugmaker Sanofi expects to get approval for the potential coronavirus vaccine it is developing with GlaxoSmithKline by the first half of next year. Francis Maguire reports.

Credit: Reuters Studio    Duration: 01:13Published

Gilead Sciences American pharmaceutical company

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62% [Video]

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62%

The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19. According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%. U.S. drugmaker Gilead Sciences reported the new data on Friday. Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial. There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.

Credit: Wochit News    Duration: 00:32Published
Gilead sparks Wall Street rally [Video]

Gilead sparks Wall Street rally

U.S. stocks rose Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:20Published
Gilead says remdesivir cuts death risk [Video]

Gilead says remdesivir cuts death risk

Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:04Published
Gilead's remdesivir gets conditional EU clearance [Video]

Gilead's remdesivir gets conditional EU clearance

The European Commission said Friday it had given conditional approval for the use of antiviral drug remdesivir in severe COVID-19 patients. As Fred Katayama reports, that makes it the region's first authorized therapy to treat the virus.

Credit: Reuters Studio    Duration: 00:59Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now announced the drug will cost $3,120 per typical treatment course for insured individuals. Research has indicated the drug could cut the recovery time for hospitalized COVID-19 patients. It could shorten satsy by several days, reports Gizmodo.

Credit: Wochit News    Duration: 00:35Published

Coronavirus disease 2019 Coronavirus disease 2019 Infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2

Israel Embassy contributes AI-based technologies to the AIIMS Delhi [Video]

Israel Embassy contributes AI-based technologies to the AIIMS Delhi

Embassy of Israel on August 11 contributed state-of-the-art artificial intelligence based technologies and high-end equipment to the AIIMS, Delhi. Contribution was made as a part of Israel-India cooperation to fight ongoing COVID-19 pandemic. "It is the most advanced medical equipment that we developed in Israel especially for fighting COVID-19. Some of it was contributed by companies, they just love India and some of it was purchased with special fund allocated by our Foreign Minister," said Israel's Envoy to India Ron Malka.

Credit: ANI    Duration: 01:58Published
Have to see critically whether it is safe, effective: AIIMS Director on Russia's COVID-19 vaccine [Video]

Have to see critically whether it is safe, effective: AIIMS Director on Russia's COVID-19 vaccine

Russia claimed to have developed vaccine for COVID-19. Speaking on it, AIIMS Director Randeep Guleria said, "If Russia's vaccine is successful, then we will have to see critically whether it is safe and effective. India has the capacity for mass production of vaccine." Russia became the first country to register for COVID-19 vaccine on August 11. One of President Putin's daughters has been given a shot of vaccination.

Credit: ANI    Duration: 01:06Published

India expresses interest in Russia's COVID-19 vaccine

The statement on the website dedicated to the "world's first registered Covid-19 vaccine" lists out India along with 20 other countries that have shown interest..
DNA

Paddleboarding Festival in Russia Draws Thousands, COVID Nightmare on Water

Russia beat the U.S. into orbit in the '60s, and might have thought they beat us in COVID-safe fun -- but looking at these images of paddleboarders packed..
TMZ.com

Centre's help in providing Covid test kits to UP must continue: Adityanath to PM

The chief minister also sought the Centre's support for purchasing HFNC equipment, used in giving high flow nasal oxygen to patients. Adityanath also apprised..
IndiaTimes

You Might Like

Related news from verified sources

Gilead shares rise on report of AstraZeneca's interest in megamerger

Shares of Gilead Sciences Inc rose as much as 3% on Monday after a report said the U.S. drugmaker had...
Reuters India - Published

AstraZeneca shares down 2% after report it approached Gilead over tie-up

Shares in Britain's AstraZeneca fell 2.1% in early trades on Monday after a report it had approached...
Reuters India - Published


Tweets about this